<DOC>
	<DOCNO>NCT00800839</DOCNO>
	<brief_summary>The goal clinical research study learn cyclophosphamide give busulfan fludarabine help prevent graft versus host disease ( GVHD - condition transplant tissue attack body transplant ) patient receive stem cell transplant . The safety drug combination also study .</brief_summary>
	<brief_title>Busulfan Fludarabine Followed Post-transplant Cyclophosphamide</brief_title>
	<detailed_description>The Study Drugs : Busulfan design bind DNA ( genetic material cell ) , may cause cancer cell die . Fludarabine design make cancer cell less able repair damage DNA . This may increase likelihood cell die . Cyclophosphamide design interfere multiplication cancer cell , may slow stop growth spread throughout body . This may cause cancer cell die . It also design suppress immune system help prevent GVHD . Study Drug Administration Transplant : If inpatient , Day -8 ( 8 day date transplant ) , receive low-level test dose busulfan needle vein 1 hour . If outpatient , Day -30 Day -8 , receive low-level test dose busulfan needle vein 1 hour day . You give anti-seizure drug help prevent seizure time receive busulfan . Your doctor explain drug give drug 's risk . Seizures rare serious side effect busulfan . On Days -8 , -6 , -4 , blood ( 1 teaspoon time ) drawn total 11 time pharmacokinetic ( PK ) test . PK test measure amount study drug body different time point . This PK test do find dose busulfan need body size day receive busulfan . On Day -6 Day -3 , receive body-specific dose busulfan vein 3 hour day . If blood level test perform reason , receive standard busulfan dose . You receive fludarabine needle vein 1 hour day receive busulfan . On Day 0 , receive donor bone marrow blood stem cell vein 1 hour . On Day +3 Day +4 , receive cyclophosphamide vein 3 hour . On Days +3 thru +5 first dose cyclophosphamide every 4 hour , receive mesna vein 30 minute total 10 dos . Mesna drug protects bladder cell damage chemotherapy drug . It use decrease risk bleed bladder . Once day start Day +7 , receive filgrastim ( G-CSF -- drug help growth white blood cell ) needle skin blood cell level reach `` recovered '' level 3 day row . Study Visits : Every day hospital outpatient visit , physical exam check symptom GVHD . Blood ( 3 teaspoon ) draw least 2 time week first 100 day transplant routine test . About 1 month transplant , every 3 month year , follow test procedure perform : - Blood ( 5 tablespoon ) draw routine test check CMV . Blood draw may repeat often , doctor think need . - Urine collect routine test . - You bone marrow aspirate biopsy check status disease . At Months 1 , 2 , 3 , 6 , 12 transplant , blood ( 4 tablespoon ) draw check status immune system . Tests procedure may repeat often study , doctor think need . Length Study : You study hospital 4 week . You take study disease get bad study doctor think best interest . Long-Term Follow-Up : After first 24 month , receive either phone call letter study doctor regular doctor 1 time year check status disease . If contacted mail , give self-addressed stamp envelope return response doctor . This investigational study . Busulfan FDA approve commercially available treatment chronic myelogenous leukemia ( CML ) . Fludarabine FDA approve commercially available treatment chronic lymphocytic leukemia ( CLL ) . Cyclophosphamide FDA approve commercially available treatment lymphoma . The use drug together possible prevention GVHD investigational . Up 40 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients high risk hematological malignancy , include induction failure treat untreated relapse . 2 . HLAidentical sibling match unrelated donor transplant eligible protocol high priority . 3 . Age 6 month 75 year . 4 . Bilirubin &lt; /= 1.5 mg/dl , serum glutamate pyruvate transaminase ( SGPT ) &lt; /= 200 IU/ml ( unless Gilbert 's syndrome ) . 5 . Calculated creatinine clearance &gt; 50mL/min use CockcroftGault equation adult patient 18 70 year old , Schwartz equation pediatric patient 6 month 17 year old . 6 . Diffusing capacity carbon monoxide ( DLCO ) &gt; 45 % predict correct hemoglobin ( report Pulmonary Function Laboratory MDACC ) . For child &lt; /= 6 year age unable perform pulmonary function test ( PFT ) , pulse oximetry &gt; /= 92 % room air . 7. leave ventricular ejection fraction ( LVEF ) &gt; /= 35 % . 1 . HIV seropositivity 2 . Uncontrolled infection . 3 . Positive Beta human chorionic gonadotropin ( HCG ) test woman child bear potential define postmenopausal 12 month previous surgical sterilization 4 . Inability sign consent</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Post-allogeneic transplantation</keyword>
	<keyword>Graft-versus-Host Disease Prophylaxis</keyword>
	<keyword>Graft-versus-Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Human Leukocyte Antigen</keyword>
	<keyword>HLA</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Mesna</keyword>
	<keyword>Cytoxan®</keyword>
	<keyword>Neosar®</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran®</keyword>
	<keyword>Fludarabine Phosphate</keyword>
</DOC>